PROGRESS & OUTCOMES

CANCER PROGRAM  2012 Annual Report
Statistical data from 2011

University of Illinois
Hospital & Health Sciences System
Changing medicine. For good.
STATEMENT FROM DR. OZER

2012 demonstrated continuing progress and success for the University of Illinois Hospital & Health Sciences System Cancer Center (UI Health Cancer Center). With the collaboration of the UI Health, we have managed to elevate the Cancer Center and the clinical cancer programs to a new level of achievement for our services and clinical research.

We have been able to achieve national recognition for the UI Health Cancer Center Program on several fronts. First of all, in the U.S. News and World Report rankings, regional recognition was awarded to both the Cancer and Urology programs. Secondly, we underwent our three year review by the American College of Surgeons, achieving an unrestricted continuation for the next three years with commendations for submitting data to the NCDB without errors (Standard 3.7); achieving greater than 6% enrollment in clinical trials for all surveyed years (Standard 5.2); offering numerous early prevention/detection programs during the surveyed years (Standard 6.2); and annually implementing several quality improvements that directly affected patient care (Standard 8.2). In addition to these achievements, under Dr. Kent Hoskins’ leadership, we have undertaken yet another milestone awarded by the American College of Surgeons: the designation as an accredited breast cancer program. This would put us in the elite category of only four such programs within the urban Chicago area. We are anticipating an application and potential review of the Breast Program to take place in the summer of 2013.

Our commitment to cancer research continues to make us the choice research university for some of the best clinicians and scientists in the field. Our work is nationally respected and supported, and our members have received several successful grants from the National Cancer Institute. Research conducted at the UI Health Cancer Center continues to help advance and enhance patient care.

Our advances in patient care have been significant. We have welcomed a number of new clinicians in Pathology, Radiology, Surgery, Medical Oncology, Gynecologic Oncology, saw the launch of a new Thoracic Oncology Program, and made significant enhancements to our Surgery, Imaging and Blood & Marrow Transplant services.

We have much to be proud of, and much to look forward to, as we build on the Cancer Center’s record of success.

Howard Ozer, MD, PhD, Director
University of Illinois Hospital & Health Sciences System Cancer Center
INTRODUCTION

The UI Health Cancer Center brings together all of the cancer-related research, education, and cancer care activities from multiple colleges and departments within the University of Illinois Hospital & Health Sciences System. Over 200 members, from a wide variety of disciplines, are linked by their dedication to their work and collaboration in the field of cancer research. From advances in clinical care to ground-breaking basic science and disparities research, the UI Health Cancer Center has become a growing force in the state’s cancer community.

New Clinical Faculty Recruited:

Satish Alapati, DDS, PhD, is an Assistant Professor of Endodontics in the College of Dentistry, at the University of Illinois Hospital & Health Sciences System. Dr. Alapati is a member of the Cancer Center’s Population Health Behavior and Outcomes program, and his research focuses on disparities in early childhood dental health.

Anjen Chenn, MD, PhD, is an Associate Professor of Pathology, in the Department of Medicine, at the University of Illinois Hospital & Health Sciences System. Dr. Chenn is a member of the Cancer Center’s Cancer Cell Signaling program, and his research focuses on the molecular mechanisms that regulate normal and brain tumor stem cell development. Check out Dr. Chenn’s Lab at http://www.uic.edu/labs/chennlab/.

Oana Danciu, MD, is an Assistant Professor, in the Department of Medicine, Section of Hematology/Oncology, at the University of Illinois Hospital & Health Sciences System. Dr. Danciu’s specialty is the treatment of breast cancers.

Nonyem Onujiogu, MD, is an Assistant Professor of Obstetrics and Gynecology, at the University of Illinois Hospital & Health Sciences System. Her specialty is the treatment of gynecological cancers.

Jalees Rehman, MD, is an Associate Professor of Medicine and Pharmacology, in the Department of Pharmacology, at the University of Illinois Hospital & Health Sciences System. Dr. Rehman is a member of the Cancer Center’s Cancer Cell Signaling program, and his research interest is the role of glutamine metabolism, glycolysis and mitochondrial function in cancer cells and stem cells.

Robert Winn, MD, is the Associate Vice President for Community-Based Practice and Director of the UI Health Lung Cancer Program. Dr. Winn’s research interest is in WNT signaling in lung cancer metastasis, and he is particularly interested in health disparities within lung cancer and developing community access to lung cancer screenings.
Remodeling of the Blood & Marrow Transplant Unit (BMT)

With a generous gift provided by Jim Perry and the Perry Family Foundation, the 10-bed Blood & Marrow Transplant Unit received a beautiful renovation that reflects the desired comfort needed by both families and patients during lengthy hospital stays for bone marrow transplants. Features of the Blood & Marrow Transplant Unit include: revised ventilation and air conditioning systems to help maintain sterile conditions and moderate temperature controls; flat-screen TVs that also function as computer monitors and contain Skype options; dimmable lighting; updated furniture, cabinetry and headboards for improvement of patient care and safekeeping of personal items; windows, lighting and peaceful decor; and comfortable chairs and overnight beds to accommodate visitors. As well, space has been allocated for families, with kitchen space and technology options available for use. Finally, all renovations utilized sustainable construction and reflect the environmentally conscious resources that are available within the University of Illinois Hospital & Health Sciences System. In addition to the renovation, funding has also been provided for additional stem cell research and placed in an endowment fund for patients who might be unable to afford their treatment.

Evelyn Goldberg Mammography Center

Aligned with the A Silver Lining Foundation mission of providing hope and treatment to all breast cancer patients, the Evelyn Goldberg Mammography Center was officially dedicated in September 2012. As a member of the University of Illinois Medical Advisory Board, Dr. Sandy Goldberg has had a long-standing relationship with the University of Illinois Hospital & Health Sciences System and within the local community, as both a breast cancer survivor and a registered dietitian. She is also the founder of the A Silver Lining Foundation. Named after Goldberg’s mother and through the generous contributions of the A Silver Lining Foundation and breast cancer survivor and author Suzanne Zaccone and the Zaccone Family Foundation, the Evelyn Goldberg Mammography Center was born. Located in the Outpatient Care Center, the UI Health Mammography Center is host to a new state-of-the-art, vacuum-assisted stereotactic biopsy machine, which enables non-surgical and minimally-invasive biopsies and collection of multiple tissue samples, with greater accuracy.

Neurological and Pulmonary Stereotactic Radiosurgery

The Radiation Oncology department received new technology in the form of Stereotactic Radiosurgery. This state of the art equipment not only allows for minimally invasive radiological treatment for brain and lung malignancies, but also greatly reduces the risk of external tissue damage and significantly reduces treatment time. This technology, states Dr. Matthew Koshy, Assistant Professor with UI Health Radiation Oncology, “allows us to visualize tumor and patient position before we begin treatment. This in turn allows us a greater deal of precision and accuracy with our radiation dose.” The greatest beneficiary of the technology is the UI Health patient population, who now has the most updated treatment options at their doorstep.
Dr. Koshy and his team with the Stereotactic Radiosurgery technology

Newly modeled room in the Blood & Marrow Transplant Unit (BMT)

Dr. Damiano Rondelli and BMT benefactor, Jim Perry, cut the ribbon on the newly-renovated BMT Unit.

Dr. Sandy Goldberg cuts the ribbon on the new Evelyn Goldberg Mammography Center.

Dr. Sandy Goldberg (left) and author and breast cancer survivor, Suzanne Vaccone (rt.)
PEDIATRIC CARE AND RESEARCH

The University of Illinois Hospital & Health Sciences System is a member of Children’s Oncology Group (COG), an NCI National Cooperative Group for pediatric cancer clinical trials. Our program is a unique joint program between UI Health, Rush University Medical Center, and John H. Stroger Hospital of Cook County.

In addition to maintaining the highest of clinical standards to treat pediatric cancers, the Children’s Oncology Group maintains several efforts to develop a variety of clinical trials that address the components of understanding, preventing and treating pediatric cancers and addressing the needs of adult survivors of pediatric cancers via therapeutic, biology, registry, cancer control, epidemiology and late-effects trials.

After a routine tri-annual COG audit (October 2012), each component, consisting of regulatory, pharmacy and patient case review from all three institutions, was passed and noted for its level of organization and meticulousness in record-keeping. “It was evident the team was committed to the program and to COG research.” In addition, the auditors commended the “organization and cohesiveness” of our three institutions, and our preparedness for the audit. It is these standards that have enabled COG and UI Health to continue bridging the gap between pediatric cancers and current treatments. Our tri-institutional arrangement is unique among COG member institutions, so this was a huge opportunity for us to showcase our model and to show that it can produce quality research. In addition, our tri-institutional agreement allows us to serve a broad range of patients and provide access to clinical trials to historically underrepresented minorities.

In 2012, with the leadership of Dr. Mary Lou Schmidt the trilateral program enrolled 98 patients in 125 clinical trials, registries, and banking protocols. With a 22.5% improvement over our 2011 progress, COG clinical trials are making a significant impact in the treatment and survival of pediatric, adolescent, and young adult cancers.

In 2013, our goal is to have at least 120 total enrollments, with at least 20 being therapeutic enrollments. We will continue to engage clinicians in various departments to raise awareness of COG trials. Dr. Schmidt will be giving presentations about COG and our tri-institutional partnership to residents, fellows, and interested clinicians. In addition, a current list of enrolling trials with eligible ages is always available by emailing Jenny Dawson-Tibbits (jniemei2@uic.edu) or Jonathan Davidson (jdavids1@uic.edu).

SURVIVORSHIP CLINIC

The UI Health Pediatric Cancer Survivorship Clinic is one of only 100 Childhood Cancer Survivorship Clinics in the U.S. The purpose of this clinic is to provide medical and psychosocial support to adult survivors of pediatric cancers. These cancers include acute leukemias, brain tumors, lymphoma, sarcoma, neuroblastoma, Wilm’s Tumor, retinoblastoma and hepatoblastoma. 66% of adult survivors of pediatric cancers will have at least one late effect from their cancer therapy, and 34% of adult survivors will have a severe or life-threatening effect. As a result, these patients require the same care and attention to their medical status, well beyond their pediatric treatment.

In 2012, the Pediatric Cancer Survivorship Clinic assessed over 100 patients, in addition to seeing patients for annual follow-up appointments. These patients have specific needs in reflection of their previous surgical, chemotherapeutic and radiation therapies, and how those therapies may affect their development into adulthood. Patients are referred to the clinic through all manners of primary and specialty health care, as well as throughout all of Illinois and its neighboring states. At the helm of this program is Mary Lou Schmidt, MD, Associate Professor and Chief of the Division of Hematology/Oncology, in the University of Illinois College of Medicine, with training in both adult and pediatric medicine.

The Survivorship Clinic is one of few programs in the city that accepts patients, particularly adult survivors, with Medicaid. As a result, Pediatric Cancer Survivorship Clinic patients have a variety of services to take advantage of, many of which are specifically designed to address the variable needs of adult survivors. Services include: neuropsychological testing from Dr. Neil Pliskin, the Director of Neuropsychology and Neurobehavior at the University of Illinois Hospital &
Health Sciences System; referrals to a Pediatric Neuropsychologist; and comprehensive appointments with our team of social workers, oncology nurses and Attending physician, Dr. Leslie Jabine, all of whom holistically assess each patient. This assessment allows for an in-depth, individualized treatment plan that reflects each patient’s full cancer history and addresses the many physical, cognitive and psychological effects that continue well into adulthood. Likewise, this addresses the current status of each patient, aligned with the Long Term Followup Guidelines, as commissioned by the Children’s Oncology Group, to develop plans for prevention and maintenance towards a long and healthy life.

RESEARCH HIGHLIGHTS
The Oncology Clinical Trials Office (OCTO)
The UI Health Oncology Clinical Trials Office is led by Dr. Arkadiusz Dudek as Medical Director and Joanna Hill as Administrative Director. The OCTO is a centralized office for clinical trials management that ensures that the regulatory, financial and clinical procedures for clinical trials are conducted in a responsible fashion, with consistency and accuracy. In addition, the OCTO utilizes a multidisciplinary approach to conducting clinical trials, which demonstrates our strong collaboration with multiple units throughout the health system. Currently, our OCTO includes a team of regulatory coordinators, data managers, and clinical research coordinators (nurses). OCTO provides our patients with the access to a variety of cancer clinical trials, which have been selected for opening based on our patient population and our community’s healthcare needs. Our clinical trial portfolio includes 76 cooperative group trials, 8 industry-sponsored trials, 12 institutional trials, and 13 externally peer-reviewed studies. We are also offering many of our clinical trials at our satellite site in Berwyn, IL at MacNeal Hospital, bringing academic innovation to a community-based practice. In 2012, a total of 116 patients were accrued to both therapeutic and non-therapeutic trials across both sites. Looking ahead to 2013, OCTO is actively seeking and accruing patients for all disease-site studies and plans to initiate a Phase I Clinical Trial Program under the leadership of Dr. Dudek and Research Coordinators Alisha Williams and Grace Rivera.

Cancer Center Seminar Series
The Cancer Center has four themed programs of research, including Carcinogenesis and Chemoprevention, which focuses on the origin of cancer and therapies that might have a preventative quality; Cancer Cell Signaling, which dissects the mechanisms of tumor development and progression; Cancer Targets, Therapeutics and Imaging, which investigates new therapies that can target the molecular survival of cancer and imaging technology utilized in both assessment and treatment of cancer; and Population Health, Behavior and Outcomes, which focuses on prevention behaviors, cancer control within the population, and the psychosocial needs of cancer survivorship. Within the context of these programs, the Cancer Center hosted 30 seminars for Cancer Center members, hospital and UI Health physicians, faculty, staff and researchers, throughout the 2012 calendar year. These seminars reflect the collaborative structure of the Cancer Center, as well as addressed issues that are timely in the national landscape of cancer. Recurrent themes included the effects of obesity and weight management as related to cancer, behavioral follow-through of patients, understanding stem cells, hormonal influences on cancer, and the influence of co-morbid factors, such as diabetes, Hepatitis C and anemia.
Cancer Center Research Forum

The Cancer Center hosted its first Cancer Center Research Forum and Poster Session on March 6, 2012. Over 120 posters were presented on the Chicago campus by UI Health Cancer Center members, students and fellows, from the Chicago, Urbana-Champaign and Rockford campuses. Keynote speaker Benita Katzenellenbogen, PhD and Swanlund Professor of Molecular and Integrative Physiology, Cell and Developmental Biology at the University of Illinois at Urbana-Champaign, addressed the event on “Genomics of Estrogen Receptor Signaling in Breast Cancer and Endocrine Resistance.” Over 250 researchers attended the event, and plans continue for a second research forum, to be held in the Fall of 2013.

Frontiers in Cancer Research Mini-Symposium

A presentation by the Cancer Center and the Department of Biochemistry and Molecular Genetics, also brought four renowned speakers in cancer research to the University of Illinois Hospital & Health Sciences System for the Frontiers in Cancer Research Mini-Symposium. This event was held at UI Health on April 4, 2012, and focused on cancer genomics, new therapeutics and personalized cancer treatments. Speakers included Elaine Mardis, PhD, Professor of Genetics and Co-Director of Technology at the Genome Institute at the Washington University School of Medicine; Louis M. Staudt, MD, PhD and Head of Molecular Biology of Lymphoid Malignancies Section with the National Cancer Institute Center for Cancer Research; William Sellers, MD and Vice President and Global Head of Oncology Research for the Novartis Institute for Biomedical Research; and Jiri Bartek, MD, PhD and Deputy Director at the Center for Genotoxic Stress Research and Professor at the Institute of Cancer Biology, with the Danish Cancer Society.

Development of Diet and Behavior Shared Resource (DBSR):

After a thorough investigation of the needs of Cancer Center members and researchers, the Diet and Behavior Shared Resource was developed by Drs. Marian Fitzgibbon and Melinda Stolley. As a novel shared resource and one of few in the United States, the DBSR aims to offer four primary services by seven expert faculty: behavioral measurement and methodology, behavioral intervention design and implementation, dietary data collection and management, and training. Additionally, the DBSR has developed a semi-annual training symposia, addressing subjects such as dietary, physical activity and fitness assessments. The symposia reflect the various collaborations of Population Health Behavior and Outcomes research program members, and are already being utilized in current research on breast and colorectal cancers. In July 2012, Dr. Lisa Tussing-Humphreys was recruited to co-lead the DBSR. Finally, the DBSR has established a presence on the Cancer Center website and is launching several marketing initiatives, with the hopes of broadening their research and enhancing current collaborations. These services are provided with the intent to enhance not only a better understanding of the effects of cancer on human diet and behavior, but also to include these factors in future research and hypotheses.

2012 RESEARCH FUNDING AWARDS AND GRANTEES

2012 American Cancer Society Grantees

The Cancer Center is honored to present 11 of our members as 2012 American Cancer Society Grantees and the research in which they are currently involved.

- Ron Gaba, MD
  Cancer Center Member; CTTI Program
  “Effects of Drug Delivery on Tumor Necrosis after Liver Chemoembolization”

- Xialong He, PhD
  Cancer Center Member; CTTI Program
  “Functional Significance of CDC42 Alternative Splicing in Ovarian Cancer”
2012 American Cancer Society Grantees
The Cancer Center is honored to present 11 of our members as 2012 American Cancer Society Grantees and the research in which they are currently involved.

Antonia Kolokythas, DDS
“Improve Detection of Oral Pre-Malignant Lesions in the Head and Neck”

Brian Murphy, PhD
Cancer Center Member; CTTI Program
“Use of Marine Bacteria to Overcome Drug Resistant Ovarian Cancer”

Miljan Simonovic, PhD
“Selection and Targeting of Selenocysteine by Human Elongation Factor”

Andrew Tsung, MD
“Targeting EGFR in Glioblastoma by Cord Blood Adult Stem Cells”

Xavier Llor, MD, PhD
Cancer Center Member; PHBO Program
“Chicago Colorectal Cancer Consortium: Colorectal Cancer in African Americans”

Joanna Burdette, PhD
Cancer Center Member; CTTI Program
“Akt Transformation of Ovarian and Fallopian Cells”

Jeremy Johnson, PharmD, PhD
Cancer Center Member; CCP Program
“Prostate Cancer Chemoprevention with Carnosol by Dual Disruption of AR/ER”

Sua Myong, PhD
“Single Molecule Investigation of DNA Repair Mechanism in Cancer”

Vitalyi Senyuk, PhD
“Role of miR-124 in EV1-mediated Oncogenesis”

2012 Junior Cancer Investigator Pilot Program
The Cancer Center funded three awards, of $30,000 each, to bring young investigators into cancer research. Investigators were within their first six years of an academic appointment.

Ron Gaba, MD
“Relationship Between gene Expression in Treated Hepatocellular Carcinoma Fixed Tissues and Tumor Response after Transarterial Chemo-embolization”

Jian Ma, PhD
“Patient-specific Molecular ‘Driver’ Mutations - Validation on Prostate Cancer Patients”

Ajay Maker, MD
“Glycolytic Inhibition of Colon Cancer Cells Increases Sensitivity to Oxidative Stress and to Death Receptor Apoptosis”
2012 Translational Cancer Research Pilot Project Awardees

The Cancer Center funded six projects, in a joint program with the University of Illinois Urbana campus. The goal of these projects is to focus on translational research and inter-campus and inter-programmatic collaborations.

Joel Schwartz, DMD, PhD
“Early Detection, Diagnosis and Genetic Susceptibility for Oral and Oralpharynx Cancer Among Diverse Populations”

Les Hanakahi, PhD
“Inositol polyphosphate in DNA double-strand break repair: a novel target for radiosensitizers”

Yingxiao Wang, PhD
“An Integrated Platform for Detection and Analysis of Invasive Breast CTCs”

Rohit Bhargava, PhD
“Center for Translation of Chemical Imaging”

Xiaolong He, PhD
“The role of ESRP1 in human ovarian cancer”

Angela Tyner, PhD
“Functions of Protein Tyrosine Kinase 6 in Prostate Cancer Progression”

PREVENTION, SCREENING AND OUTREACH

Familial Breast Cancer Program (FBCP)

The clinic, created by Kent Hoskins, MD, opened in March 2011, to provide comprehensive care for individuals and families at an increased risk for breast and other cancers, due to hereditary predisposition. The program has expanded rapidly since inception, including the recruitment of a licensed genetic counselor, Kimberly Vande Wydeven, MS, CGC. The FBCP team provides cancer risk assessment, genetic counseling, coordination of genetic testing, and personalized cancer risk reduction recommendations.

2012 welcomed 130 new patients, who were evaluated in the clinic, and nearly 300 patient visits. The FBCP has also enjoyed a high rate of patient referrals from physicians within UI Health and from outside hospitals. Clinics are held weekly, and genetic counselor, Ms. Vande Wydeven, is available for same-day, urgent consult and testing needs. The team has created unique educational materials and resource guides tailored to the patient population.

The FBCP continues to grow both in patient volume and research activity. The program joined an international consortium of researchers studying genetic susceptibility to breast cancer among ethnic minority populations, and several investigator-initiated research projects were launched in 2012. Several more are planned for 2013, including expansion of the program’s research portfolio to include novel therapeutic trials for women with hereditary breast cancer.
2012 Outreach - Organizational
Imerman Angels 1 on1 Cancer Support is a local organization with a global mission: to provide free, mentored, individual support to any cancer fighter, survivor and caregiver, worldwide. The University of Illinois Hospital & Health Sciences System Cancer Center is proud to announce that Dr. Howard Ozer has joined the Imerman Angels Medical Advisory Board. Dr. Ozer’s role helps Imerman Angels provide the most updated research and understanding of cancer, therapies, treatments and the various resources that exist for cancer fighters, survivors and caregivers.

2012 Outreach - Prevention and Screening Activities
Under the leadership of Rick Kittles, PhD and Associate Professor of Medicine in the College of Medicine, the UI Health Cancer Center Outreach Program participates in community education, encouragement and cancer screening recruitment within the surrounding population. With the goal of eliminating health disparities, the UI Health Cancer Center Outreach Programs addresses cancer prevention, healthcare screenings, access to cancer care and provisional systems for those facing a cancer diagnosis.

April 7, 2012
Hepatitis C “Do You Know the Facts”
Living Room Cafe
Education and screening of community members for Hep-C
Cancer prevention and early detection materials and giveaways, provided by American Cancer Society Illinois Division

April 17, 2012
Minority Cancer Awareness Week “State of the Cancer Union: Minority Report”
Northwestern University
Co-sponsored by the UIC Office of Engagement and Health Equity, with the Robert H. Lurie Comprehensive Cancer Center. Presentations by medical students and faculty, regarding genetics and its link to cancer in African Americans

April 20, 2012
ACS Legislative Breakfast on Cancer Disparities, Northwestern Memorial Hospital
Co-sponsored by the UIC Office of Engagement and Health Equity, in partnership with the American Cancer Society, Illinois Division, Dr. Vince Freeman presented and spoke to Legislative members, medical students and community members regarding Cancer statistics and its link to Cancer in African Americans.

April 20, 2012
21st Century Initiative “Race, Science, and the Politics of Trust”, Chicago State University
Presentation by Dr. Kittles, about understanding genetic variation as it impacts knowledge on ancestry and health in the African American population and its impact on the future.

April 24, 2012

May 7, 2012
MSEIP Lecture Series, “Using Genetics to Trace African American Ancestry”, East West University

June 16, 2012
Thapelo Institute 10th Annual Health and Fitness Men’s Expo, Malcolm X College
Participation by Dr. Kittles in a panel discussion on “The Prostate and Cancer: Everything you need to know.”
August 19, 2012
House of Hope, Fit Festival 2012
Participation by Dr. Kittles’ Lab, in the recruitment, education and screening of community members for Prostate Cancer, via Public Screening Announcements.

September 2-5, 2012
African Festival of Life, Washington Park
In partnership with the American Cancer Society Illinois Division and co-sponsored by the UIC Office of Engagement and Health Equity, Victor LaGroon, Rick Kittles PhD, Xavier Llor, MD, PhD and Karriem Watson, MD, MPH, participated with ACS volunteers and staff in engaging community members in cancer prevention information and providing referral resources via brochures and flyers.

September 18, 2012
First Ladies Health Initiative, Rock of Ages Baptist Church
Co-sponsored by the UIC Office of Engagement and Health Equity, Dr. Kittles’ Lab participated in the recruitment, education and screening of community members for Prostate Cancer via Public Screening Announcements.

October 2012
Chicago Fire vs. DC United, Honoring Breast Cancer Awareness
As an official partner of the University of Illinois Hospital & Health Sciences System, the Chicago Fire honored breast cancer patients, survivors and caregivers with a match against the D.C. United. The players wore pink uniforms and created a video presentation about the importance of breast cancer screening.

October 25, 2012
Co-sponsored by CCTS/CERC and UIC Office of Engagement and Health Equity.

November 3, 2012
Veterans Health and Wellness Resource Fair, Malcolm X College
Leave No Veteran Behind, Jesse Brown VA, City of Chicago
Co-sponsored by the UIC Office of Engagement and Health Equity Program, the Kittles’ Lab participated in the recruitment, education and screening of community members for Prostate Cancer and Hepatitis-C.

2012 Outreach - Consortiums
BC Task Force
The goals of the CERC University of Illinois Hospital & Health Sciences System Center for Breast Health Excellence Initiative are to investigate the needs of the local communities and construct education initiatives for these communities. Led by Carol Ferrans, PhD, RN, FAAN, these initiatives include accessible and cost-effective screening and mammograms, education about breast cancer prevention, and provisions for consistent treatment options for those with a breast cancer diagnosis. Within the context of the UI Health community, the Breast Cancer Task Force is exploring how our campus partners and community members can best serve patients and those with higher risk factors, thereby improving outcomes related to breast cancer.

Several efforts were produced during 2012, to establish these initiatives. In October 2012, a Breast Cancer Town Hall Forum was held. This demonstrated that the information presented to women about breast health had a lasting impression and was a launchpad for patient-physician conversations about breast cancer and current clinical and
translational research. Additionally, a pairing with the Susan G. Komen Foundation unveiled the importance of community engagement throughout the research process, particularly by infiltrating faith-based locations and congregations. These pairings resulted in educational opportunities and community access to screenings and mammograms. Finally, continuing efforts to develop non-profit outreach and training have resulted in partnering with “Sisters Working It Out,” which has the potential to increase participation and inclusion of African American women in these important strides against breast cancer.

**Big Ten Cancer Research Consortium**

Launched in 2012, the Big Ten Cancer Research Consortium is the research component to the athletic conference known as the Big Ten. With a recent expansion to a total of 14 institutions, the Big Ten Cancer Research Consortium is actively developing a gateway for collaboration between the universities of the Big Ten, to increase science-driven research, launch novel clinical trials, and provide patients with greater treatment opportunities than any one institution might have. Included in this consortium are: the University of Illinois, Indiana University, the University of Iowa, the University of Maryland, the University of Michigan, Michigan State University, the University of Minnesota, the University of Nebraska, Northwestern University, the Ohio State University, Penn State University, Purdue University, Rutgers University and the University of Wisconsin.
Notice: When comparing survival rates between your cancer program and all other CoC-accredited cancer programs: if the confidence intervals of stage-specific or overall survival rates overlap after five years, then there is no statistical difference between survival rate of patients at your facility with that of other CoC-accredited cancer programs.
Age at Diagnosis for 2011 Analytic Breast Cases

2007 Stage 0 to 4 Analytic Breast Cases
WHAT IS TNM STAGING?


Staging is the manner in which the extent of cancer is determined by a physician. In addition to classifying the size and location of a tumor, it also enables a physician to establish the appropriate modality of treatment and prognosis. This includes assessing which organ systems may be affected and identifying the therapies that will offer the greatest benefit. As a result of their composition and location, not all cancers are evaluated in this manner. Examples of this would be blood cancers and leukemias, which lack the presence of a solid tumor, but have a greater cellular metastasis. However, the TNM system is a standard in cancer care and is used by most national governing bodies of cancer treatment and research, to form a universal understanding of cancer across organ sites.

The “T” in the TNM system refers to the extent of the tumor itself, in regards to the tumor’s molecular and cellular composition, size, and manner in which the tumor has developed within and/or across organ and tissue structures.

The “N” in the TNM system refers to a tumor’s potential spread to nearby lymph nodes. When a tumor has spread to regional lymph nodes, therein lies the possibility of lymphatic involvement and/or further metastasis to other organs via travel through the lymphatic system.

The “M” in the TNM system refers to metastasis or spread of the tumor to a distance from its primary site.

Within the TNM staging structure, the combination of these factors determines a stage for each cancer and within each organ site.
## PRIMARY SITE TABLE 2011

<table>
<thead>
<tr>
<th>PRIMARY SITE</th>
<th>TOTAL</th>
<th>CLASS</th>
<th>N/A</th>
<th>SEX</th>
<th>AJCC STAGE GROUP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL SITES</td>
<td>1438</td>
<td>1181</td>
<td>257</td>
<td>742</td>
<td>696</td>
</tr>
<tr>
<td>ORAL CAVITY</td>
<td>65</td>
<td>62</td>
<td>3</td>
<td>45</td>
<td>20</td>
</tr>
<tr>
<td>LIP</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TONGUE</td>
<td>23</td>
<td>22</td>
<td>1</td>
<td>16</td>
<td>7</td>
</tr>
<tr>
<td>OROPHARYNX</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>HYOPHARYNX</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>OTHER</td>
<td>41</td>
<td>39</td>
<td>2</td>
<td>28</td>
<td>13</td>
</tr>
<tr>
<td>DIGESTIVE SYSTEM</td>
<td>340</td>
<td>288</td>
<td>52</td>
<td>214</td>
<td>125</td>
</tr>
<tr>
<td>ESOPHAGUS</td>
<td>9</td>
<td>8</td>
<td>1</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>STOMACH</td>
<td>21</td>
<td>20</td>
<td>1</td>
<td>16</td>
<td>5</td>
</tr>
<tr>
<td>COLON</td>
<td>83</td>
<td>65</td>
<td>16</td>
<td>47</td>
<td>36</td>
</tr>
<tr>
<td>RECTUM</td>
<td>34</td>
<td>26</td>
<td>8</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>ANUS/ANAL CANAL</td>
<td>15</td>
<td>10</td>
<td>5</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>LIVER</td>
<td>98</td>
<td>91</td>
<td>7</td>
<td>73</td>
<td>25</td>
</tr>
<tr>
<td>PANCREAS</td>
<td>42</td>
<td>38</td>
<td>4</td>
<td>27</td>
<td>15</td>
</tr>
<tr>
<td>OTHER</td>
<td>38</td>
<td>30</td>
<td>8</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>RESPIRATORY SYSTEM</td>
<td>126</td>
<td>105</td>
<td>21</td>
<td>77</td>
<td>40</td>
</tr>
<tr>
<td>NASAL/SINUS</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>LARYNX</td>
<td>34</td>
<td>12</td>
<td>2</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>LUNG/BRONCHUS</td>
<td>138</td>
<td>91</td>
<td>17</td>
<td>64</td>
<td>44</td>
</tr>
<tr>
<td>OTHER</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PRIMARY SITE</td>
<td>TOTAL</td>
<td>CLASS</td>
<td>N/A</td>
<td>SEX</td>
<td>AJCC STAGE GROUP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLOOD &amp; BONE MARROW</td>
<td>121</td>
<td>70</td>
<td>51</td>
<td>60</td>
<td>61</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>67</td>
<td>37</td>
<td>30</td>
<td>33</td>
<td>34</td>
</tr>
<tr>
<td>MULTIPLE MYELOMA</td>
<td>26</td>
<td>17</td>
<td>9</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>OTHER</td>
<td>28</td>
<td>16</td>
<td>12</td>
<td>11</td>
<td>17</td>
</tr>
<tr>
<td>BONE</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>CONNECT/SOFT TISSUE</td>
<td>22</td>
<td>20</td>
<td>2</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>SKIN</td>
<td>93</td>
<td>69</td>
<td>5</td>
<td>46</td>
<td>47</td>
</tr>
<tr>
<td>MELANOMA</td>
<td>79</td>
<td>75</td>
<td>4</td>
<td>39</td>
<td>40</td>
</tr>
<tr>
<td>OTHER</td>
<td>14</td>
<td>13</td>
<td>1</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>BREAST</td>
<td>160</td>
<td>131</td>
<td>29</td>
<td>4</td>
<td>156</td>
</tr>
<tr>
<td>FEMALE GENITAL</td>
<td>51</td>
<td>51</td>
<td>20</td>
<td>0</td>
<td>51</td>
</tr>
<tr>
<td>CERVIX UTERI</td>
<td>16</td>
<td>7</td>
<td>9</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>UTERUS</td>
<td>19</td>
<td>14</td>
<td>5</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>OVARY</td>
<td>12</td>
<td>9</td>
<td>3</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>VULVA</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>OTHER</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>MALE GENITAL</td>
<td>106</td>
<td>88</td>
<td>18</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>PROSTATE</td>
<td>101</td>
<td>84</td>
<td>17</td>
<td>101</td>
<td>0</td>
</tr>
<tr>
<td>TESTIS</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>OTHER</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
## PRIMARY SITE

<table>
<thead>
<tr>
<th>PRIMARY SITE</th>
<th>TOTAL</th>
<th>CLASS</th>
<th>N/A</th>
<th>MALE</th>
<th>FEM</th>
<th>0</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
<th>UNK</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>URINARY SYSTEM</td>
<td>89</td>
<td>79</td>
<td>10</td>
<td>57</td>
<td>32</td>
<td>5</td>
<td>25</td>
<td>11</td>
<td>17</td>
<td>18</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>BLADDER</td>
<td>24</td>
<td>21</td>
<td>3</td>
<td>16</td>
<td>8</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>KIDNEY/RENAL</td>
<td>62</td>
<td>55</td>
<td>7</td>
<td>39</td>
<td>23</td>
<td>0</td>
<td>21</td>
<td>8</td>
<td>11</td>
<td>13</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>OTHER</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>BRAIN &amp; CNS</td>
<td>88</td>
<td>81</td>
<td>7</td>
<td>38</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>BRAIN (BENIGN)</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>BRAIN (MALIGNANT)</td>
<td>39</td>
<td>37</td>
<td>2</td>
<td>24</td>
<td>15</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>OTHER</td>
<td>43</td>
<td>38</td>
<td>5</td>
<td>11</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>43</td>
</tr>
<tr>
<td>ENDOCRINE</td>
<td>40</td>
<td>33</td>
<td>7</td>
<td>13</td>
<td>27</td>
<td>0</td>
<td>13</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>19</td>
</tr>
<tr>
<td>THYROID</td>
<td>21</td>
<td>19</td>
<td>2</td>
<td>3</td>
<td>18</td>
<td>0</td>
<td>13</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>OTHER</td>
<td>19</td>
<td>14</td>
<td>5</td>
<td>10</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>LYMPHATIC SYSTEM</td>
<td>99</td>
<td>75</td>
<td>24</td>
<td>48</td>
<td>51</td>
<td>0</td>
<td>25</td>
<td>14</td>
<td>15</td>
<td>25</td>
<td>18</td>
<td>2</td>
</tr>
<tr>
<td>HODGKIN'S DISEASE</td>
<td>10</td>
<td>8</td>
<td>2</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>NON-HODGKIN'S</td>
<td>89</td>
<td>67</td>
<td>22</td>
<td>43</td>
<td>46</td>
<td>0</td>
<td>25</td>
<td>11</td>
<td>11</td>
<td>23</td>
<td>17</td>
<td>2</td>
</tr>
<tr>
<td>UNKNOWN PRIMARY</td>
<td>23</td>
<td>19</td>
<td>4</td>
<td>14</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>23</td>
</tr>
</tbody>
</table>

Number of cases excluded: 0
This report INCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases